Abstract: An internal combustion engine includes an engine lubrication fluid storage system with a primary storage volume and a secondary storage volume that is separate from the primary storage volume. The secondary storage volume is linked to the primary storage volume with a fluid flow path that is throttled so that lubrication fluid is stored in the secondary storage volume during engine operation, and drains from the secondary storage volume to the primary storage volume when the engine is not running.

Abstract: An internal combustion engine includes an engine lubrication fluid system with a main rifle for distribution of filtered lubrication fluid to a plurality of engine components through a plurality of secondary rifles connected to the main rifle. The system also includes a bypass for bypassing the filter in response to certain engine operating conditions. The bypass is connected to at least one of the secondary rifles so that unfiltered lubrication fluid is not provided to certain engine components under filter bypass conditions, and provided directly to certain other engine components for which unfiltered lubrication fluid is less problematic.

Abstract: An internal combustion engine includes an engine lubrication fluid system with a main rifle for distribution of filtered lubrication fluid to a plurality of engine components through a plurality of secondary rifles connected to the main rifle. The system also includes a bypass for bypassing the filter in response to certain engine operating conditions. The bypass is connected to at least one of the secondary rifles so that unfiltered lubrication fluid is not provided to certain engine components under filter bypass conditions, and provided directly to certain other engine components for which unfiltered lubrication fluid is less problematic.

Abstract: An internal combustion engine includes an engine lubrication fluid storage system with a primary storage volume and a secondary storage volume that is separate from the primary storage volume. The secondary storage volume is linked to the primary storage volume with a fluid flow path that is throttled so that lubrication fluid is stored in the secondary storage volume during engine operation, and drains from the secondary storage volume to the primary storage volume when the engine is not running.

Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient.

Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient.

Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient.

Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient.

Abstract: The present invention comprise a flag illumination assembly that both (i) illuminates an associated flag from a vertical edge of the flag and (ii) swivels with the edge of the flag as the flag is tossed in the wind. The foregoing facilitates illumination of the flag regardless of the direction of the wind. Further, a simmering effect is often created as a result of natural undulations of the flag in wind relative to the beams of light being directed thereon from the illumination assembly.

Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient.

Abstract: Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Abstract: The present invention comprise a flag illumination assembly that both (i) illuminates an associated flag from a vertical edge of the flag and (ii) swivels with the edge of the flag as the flag is tossed in the wind. The foregoing facilitates illumination of the flag regardless of the direction of the wind. Further, a simmering effect is often created as a result of natural undulations of the flag in wind relative to the beams of light being directed thereon from the illumination assembly.

Abstract: Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula 1.

Abstract: The present invention relates to conductive adhesives that may be used within an image forming apparatus. The image forming apparatus may include printing devices such as inkjet printers, electrophotographic printers, copiers, faxes, all-in-on devices or multi-functional devices. The conductive resins may be applied to the shaft of foam rolls suitable for transporting and applying image forming material in an image forming apparatus such as a laser printer.

Abstract: A method and apparatus to clear the accumulation of toner particles from a doctor element by periodically reversing a bias field between a doctor element and a developer member. The developer member may be biased to a first electrical potential while the doctor element may be biased to a second electrical potential. The second electrical potential may be higher than the first electrical potential. The doctor element and the developer member may be biased from a single voltage supply and a voltage dividing circuit. A bias reversing circuit may cause the second electrical potential to fall, at least temporarily, below that of the first electrical potential when power from the voltage supply is removed. The bias reversing circuit may also cause the first electrical potential to fall with a longer time constant than that of the second electrical potential when power from the voltage supply is removed.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.